Estrella Immunopharma (ESLAW) Competitors $0.09 -0.01 (-5.26%) As of 03/11/2025 12:07 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends ESLAW vs. ATNFW, SXTPW, DRTSW, WENAW, APLMW, BCTXW, CDIOW, CTCXW, CELUW, and CEROWShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Anew Medical (WENAW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Celularity (CELUW), and CERo Therapeutics (CEROW). These companies are all part of the "biotechnology" industry. Estrella Immunopharma vs. 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Anew Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Carmell Celularity CERo Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and Estrella Immunopharma (NASDAQ:ESLAW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation. Does the media prefer ATNFW or ESLAW? In the previous week, 180 Life Sciences and 180 Life Sciences both had 1 articles in the media. 180 Life Sciences' average media sentiment score of 1.87 beat Estrella Immunopharma's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Very Positive Estrella Immunopharma Neutral Is ATNFW or ESLAW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Estrella Immunopharma N/A N/A N/A Which has preferable earnings & valuation, ATNFW or ESLAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AEstrella ImmunopharmaN/AN/AN/AN/AN/A Does the MarketBeat Community believe in ATNFW or ESLAW? 180 Life Sciences and Estrella Immunopharma both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/AEstrella ImmunopharmaN/AN/A Summary180 Life Sciences beats Estrella Immunopharma on 1 of the 1 factors compared between the two stocks. Remove Ads Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLAW vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$114.77M$5.67B$8.01BDividend YieldN/A3.69%4.89%4.03%P/E RatioN/A3.2223.8318.90Price / SalesN/A4,252.28378.33118.45Price / CashN/A13.0138.0534.62Price / BookN/A36.026.844.18Net IncomeN/A-$87.82M$3.19B$246.59M7 Day PerformanceN/A-1.28%-2.49%-3.40%1 Month PerformanceN/A-2.39%-7.51%-9.30%1 Year PerformanceN/A95.80%8.62%0.65% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAWEstrella ImmunopharmaN/A$0.09-5.3%N/A+50.3%$0.00N/A0.00N/AGap DownATNFW180 Life SciencesN/A$0.01-3.4%N/A+21.4%$0.00N/A0.007Positive NewsSXTPW60 Degrees PharmaceuticalsN/A$0.02-8.5%N/A-62.5%$0.00$502,409.000.002Positive NewsDRTSWAlpha Tau MedicalN/A$0.22-2.7%N/A-17.3%$0.00N/A0.0080WENAWAnew MedicalN/A$0.04-0.3%N/AN/A$0.00N/A0.00N/AGap DownAPLMWApollomicsN/A$0.01-30.0%N/A-73.7%$0.00N/A0.0059Positive NewsHigh Trading VolumeBCTXWBriaCell TherapeuticsN/A$0.09-7.8%N/A-93.6%$0.00N/A0.008Positive NewsGap DownCDIOWCardio DiagnosticsN/A$0.04-12.5%N/A-59.2%$0.00$35,688.000.007Positive NewsGap DownCTCXWCarmellN/A$0.03+6.8%N/A-85.2%$0.00$32,839.000.0014Positive NewsGap DownCELUWCelularityN/A$0.07-40.8%N/A+20.6%$0.00$48.20M0.00220Positive NewsGap DownHigh Trading VolumeCEROWCERo TherapeuticsN/A$0.01-13.5%N/A-82.7%$0.00N/A0.008Positive NewsGap Up Remove Ads Related Companies and Tools Related Companies 180 Life Sciences Competitors 60 Degrees Pharmaceuticals Competitors Alpha Tau Medical Competitors Anew Medical Competitors Apollomics Competitors BriaCell Therapeutics Competitors Cardio Diagnostics Competitors Carmell Competitors Celularity Competitors CERo Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ESLAW) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersFormer CIA to Trump – Will you Shut down this secret lab?Deep in the sands of New Mexico lies a government lab so secret it makes Area 51 look like a tourist spot… ...Paradigm Press | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMarch 18th: Gold SHOCK? On March 18th, an event is taking place that could completely shock the market. Stocks could go ballistic…...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredMusk’s real agenda in Washington… In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | SponsoredDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
